Health Maintenance and Olmesartan

Summary of research on aging and OlmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. taken from article Science behind olmesartan

Although uncontrolled confounding might still exist, (this was a short term study) olmesartan does not seem to increase cardiovascular risk compared with losartan. ¹⁾

The ROADMAP study will answer the question whether an ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. ²⁾

Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. ³⁾

The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. ⁴⁾

Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. ⁵⁾

⁶⁾

Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. ⁷⁾

In conclusion, there is no robust signal for harm with olmesartan use. ⁸⁾

When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. ⁹⁾

These articles have identified holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. ¹⁰⁾

include the ability to:

• decrease the incidence and progression of Alzheimer's disease and dementia¹¹⁾
• prevent migraines¹²⁾
• inhibit liver fibrosis and aid liver healing¹³⁾
• reduce insulin resistance in rats¹⁴⁾
• 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats¹⁵⁾
• protect the mitochondria from age-associated damage from oxidation¹⁶⁾
• play a protective role against proliferative diabetic retinopathy ¹⁷⁾
• reduce liver fibrosis¹⁸⁾
• treatment of anxiety and stress-related disorders¹⁹⁾
• reduce oxidative damage²⁰⁾ and limit aging ^{21) 22)}

to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:

• protect the heart from damage from inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. in myocarditis²³⁾
• ameliorate acute experimental autoimmuneA condition or disease thought to arise from an overactive immune response of the body against substances and tissues normally present in the body myocarditis, in rats, suppressing cytotoxic myocardial injury ²⁴⁾
• prevent acute left ventricular dysfunction²⁵⁾
• lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation²⁶⁾
• act as an antiarrhythmic²⁷⁾
• block the production of Angiotensin II, thus improving mortality rates in heart failure patients²⁸⁾
• This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy. ²⁹⁾
• Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations. ^{30) 31)}

80mg single dose vs 6hrlydosing

4 hourly compared to 6 hourly dosing

In August 2002, Trevor Marshall and Frances Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARB caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.

In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss³²⁾. That would be 9-10 tablets of Olmetec daily for a 64 Kg human

• prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes ³³⁾
• reduce the volume of atherosclerotic plaques^{34) 35)}
• mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).³⁶⁾
• significantly remodel and destiffen the arterial wall material during long-term treatment ³⁷⁾

that olmesartan and other ARBs possess various ways of protecting the kidneys from the effects of inflammation and cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. damage:

• in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization ³⁸⁾
• in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition ³⁹⁾
• results suggest olmesartan can help decrease plasma AGE levels in patients on HD ⁴⁰⁾
• renal protective effects of olmesartan may be better than those of other ARBs ⁴¹⁾
• olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects ⁴²⁾

• treatment with olmesartan inhibited bone loss ⁴³⁾
• olmesartan protects endothelial cells against oxidative stress-mediated cellular injury ⁴⁴⁾
• decreases viability of malignant cell lines⁴⁵⁾
• carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques ⁴⁶⁾
• improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan ⁴⁷⁾
• improvement of glycemic control & insulin resistance was only observed in olmesartan group ⁴⁸⁾
• OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes ⁴⁹⁾
• prevention of microalbuminuria in patients with type 2 diabetes and hypertension ⁵⁰⁾

Patients receiving the highest dose of olmesartan (40 and 80 mg) had an inward carotid remodeling and were shifted toward a lower elastic modulus at a given circumferential wall stress, indicating an improvement in the intrinsic elastic properties of the carotid artery wall material. These data suggest that 40 and 80 mg olmesartan were able to significantly remodel and destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.

hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint ⁵¹⁾